focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Totally agree with you Dave_1.
Forgot to include the tweet link
https://mobile.twitter.com/carlsmythe/status/1384784035017265153
Trading_dad
@SkinCrypto
·
17h
is there a risk of having it too sensitive? as stupid as that may sound, If someone had only 1 virus particle that could that not be easily fought by body and thus not spread it any further?
Carl’s reply
That’s not stupid at all. We DO have a sense of this.
The point is that we can dial the assay sensitivity up or down to achieve whatever it is that a customer wants out of the test.
9:20 am · 21 Apr 2021·
Meant to type ‘have the same exhilarating’
Do you genuine holders the same exhilarating feel as I do about the clinical results? After seeing Carl’s tweet comparing our device detection of the virus to AVCT, I’m thrilled to the bones waiting for his final analysis!
Spot the traders.
Carl’s tweet
‘I know exactly what Ct levels are likely no longer infectious. ‘
Great work from Carl and his team, their dedication will help up tremendously to save lives and getting back to normality.
This poster from AVCT must be very scared of Carl’s devotion to achieve a perfect COVID testing device.
https://twitter.com/carlsmythe/status/1384619715931242497
VistaMan
@man_vista
Have you looked at the #AVCT RNS at all? Please read and understand the purpose relative to "infectious" people and the CT value chosen for the validation.
Carl’s reply
I can do better than that. I know exactly what Ct levels are likely no longer infectious.
Attempting to judge that circumstance using an LFT is a route to failure.
I rather prefer to find presymptomatics.
Because that’s what all the agencies actually want
https://twitter.com/man_vista/status/1384582651173085186
kev t
@Billsam390 asked
Hi Carl
Hope our test results are as good as AVCT's announced this morning.?
Are there advantages of our test over AVCT's that might make it more commercial?
Carl’s answer
As good?
Here’s the thing.
1.Lateral flow tests are not terribly sensitive
2. AVCT selected clinical samples with relatively high viral loads and find their test can identify most of them.
3. Going forward, we need to be able to screen people to find asymptomatics.
https://twitter.com/carlsmythe/status/1384522354785726471
Casper we can spot genuine holders and traders way before they turn up.
Precisely Casper, that’s why I’m very disappointedly with AVCT’s RNS.
StarKnight: my conclusion matches yours. Seems like they just wanted to get it out to the market regardless that had they spent more time, they could improve it to better standards.
Cando66 I am a bit disappointed with AVCT, the RNS was quite vague about the ct value they used.
Having followed Carl’s tweets, we know that high sensitivity can be achieved easily by using lower ct levels, but will miss infectious people with low viral load. These in effect will result in more spreading of the virus.
I hope our RNS will show more detailed analytical values that was used by Carl and his team on this final clinical test. Also, hope Carl used more sample size than 90!
I was hoping for AVCT to use high Ct value to improve the quality of their analysis, thus when their device is used, it would pick up those with less viral load.
Yes low sample size and they used ct>26, but did not state what ct value. Carl said we are using ct value of 34, which is 2-3 orders of magnitude FEWER virus particles. I think in terms of analytical quality used, Carl is consistent as not to use lower ct value to obtain high sensitivity result.
Ticked up
Cannot get a quote for £1k buy.
Sorry meant to type heartbreaking.